Generic Name
Propylthiouracil
FDA approval date: July 28, 1947
Classification: Thyroid Hormone Synthesis Inhibitor
Form: Tablet
What is Propylthiouracil?
Propylthiouracil tablets, USP are indicated: in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment